Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 9/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.55 |
| ▸ | PDE8A | O60658 | 1/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161254 | 0.88 | CCNE2 (0.52) | YTHDC1HSP90AA1HSP90AB1PDE8ACCNE2 | |
| SCHEMBL29366555 | 0.88 | HSP90AA1 (0.54) | YTHDC1HSP90AA1HSP90AB1ADORA2AHPGD | |
| SCHEMBL14441142 | 0.88 | HSP90AB1 (0.54) | YTHDC1HSP90AA1HSP90AB1ADORA2AHPGD | |
| SCHEMBL30496438 | 0.88 | YTHDC1 (0.56) | YTHDC1PDE8ACCNE2CCNE1CDK2 | |
| SCHEMBL21801296 | 0.88 | YTHDC1 (0.56) | YTHDC1PDE8ACCNE2CCNE1CDK2 | |
| SCHEMBL5471657 | 0.88 | HSP90AA1 (0.54) | YTHDC1HSP90AA1HSP90AB1ADORA2AHPGD | |
| SCHEMBL3389606 | 0.87 | HSP90AB1 (0.71) | HSP90AA1HSP90AB1ADORA2AHDAC4HDAC1 | |
| SCHEMBL29366455 | 0.87 | HSP90AB1 (0.71) | HSP90AA1HSP90AB1ADORA2AHDAC4HDAC1 | |
| SCHEMBL5461518 | 0.87 | HSP90AA1 (0.53) | YTHDC1HSP90AA1HSP90AB1ADORA2AHPGD | |
| SCHEMBL5458838 | 0.86 | YTHDC1 (0.76) | YTHDC1HSP90AA1HSP90AB1PDE8AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-12157739-B2 | Hypoxanthine compounds | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-12-03 | — | — | US | disclosed |
| CN-115244054-B | Crystals of hypoxanthine compound | 橘生药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-113302196-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-112673008-B | Hypoxanthine compounds | 橘生药品工业株式会社 | 2023-07-18 | — | — | CN | disclosed |
| US-20230183241-A1 | CRYSTAL OF A HYPOXANTHINE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-4092028-A1 | CRYSTAL OF HYPOXANTHINE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2022-11-23 | — | — | EP | disclosed |
| CN-115244054-A | Crystals of hypoxanthine compound | 橘生药品工业株式会社 | 2022-10-25 | — | — | CN | disclosed |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| US-20220064196-A1 | EGFR Inhibitors, Compositions and Methods Thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-2220091-A2 | REVERSE TRANSCRIPTASE INHIBITORS | Ardea Biosciences, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | VERNALIS ( R & D) LTD. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | VERNALIS ( R & D) LTD. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | VERNALIS ( R & D) LTD. (GB) | 2009-07-16 | — | — | US | disclosed |
| WO-2009079412-A2 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2004648-A1 | PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (R&D) Limited (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| WO-2007034185-A1 | PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (R & D) LTD. (GB) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007034185-A1 | PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (R & D) LTD. (GB) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157739-B2 | Hypoxanthine compounds | HPRT1, APRT, IMPDH1 | YTHDC1 651/4885HSP90AA1 2003/4885HSP90AB1 2313/4885 |
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | YTHDC1 632/4885HSP90AA1 4068/4885HSP90AB1 3579/4885 |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | HSP90AA1, HSP90AB1, HSP90AB2P | YTHDC1 1015/4885HSP90AA1 1/4885HSP90AB1 2/4885 |
| US-20220064196-A1 | EGFR Inhibitors, Compositions and Methods Thereof | EGFR, ERBB2, ERBB3 | YTHDC1 4761/4885HSP90AA1 1625/4885HSP90AB1 963/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | YTHDC1 533/4885HSP90AA1 1571/4885HSP90AB1 1097/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | YTHDC1 2508/4885HSP90AA1 2895/4885HSP90AB1 2755/4885 |
| US-20230183241-A1 | CRYSTAL OF A HYPOXANTHINE COMPOUND | HPRT1, TPMT, NUDT1 | YTHDC1 1206/4885HSP90AA1 1478/4885HSP90AB1 1663/4885 |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, CGAS, MAVS | YTHDC1 3968/4885HSP90AA1 1171/4885HSP90AB1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.